Stereotactic radiosurgery for trigeminal neuralgia: Experience from 1,000 PatientsDouglas Kondziolka, MD, MSc1, Hideyuki Kano, MD, PhD2, Ajay Niranjan, MCh1, L. Dade Lunsford, MD1, John C. Flickinger, MD31Department of Neurological Surgery, University of Pittsburgh 2 3Department of Radiation Oncology, University of Pittsburgh Keywords: pain, trigeminal neuralgia, gamma knife, radiosurgery, outcome
Preview Data Shares:
Ask Questions of this Manuscript:
Trigeminal neuralgia is a severe and debilitating pain
disorder for which many patients become medically refractory. Stereotactic radiosurgery is the least
invasive surgical option for patients with trigeminal neuralgia.
The purpose of this study was to evaluate longer-term outcomes and the durability of pain relief after radiosurgery, and the evolution of the technique over time.
Over a 19 year interval, gamma knife stereotactic radiosurgery (GKSR) was performed in 1,000 patients with trigeminal neuralgia. In the majority of patients MRI stereotactic guidance was used to deliver a single 4mm isocenter and a maximum dose of 80 Gy. We evaluated detailed outcomes in a subset of 503 medically refractory
patients and stratified outcomes according to a validated rating scale. These patients were evaluated up to 2009 to allow for longer term outcomes. Patients
were evaluated up to 16 years after GKSR; 107
patients had over five years of follow-up.
The median patient age was 70 years (range,16–99 years). 605 were female and 395 were male. The average duration of trigeminal neuralgia pain was seven years (max, 50).
In our comprehensive review of the first 503 patients, 93% had pain relief using the Barrow Neurological Institute
(BNI) scale. Favorable outcomes
(BNI scores I-IIIb) were achieved in 75% at 1 year, 59% at 3 years, 43% at 5
years and 29% at 10 years. A faster initial
pain response was seen in patients with typical trigeminal neuralgia (p=0.014),
patients without prior surgery (p=0.014), and patients with pain < 3
years (p=0.012). Two hundred forty three patients (51%) reported some recurrent
pain 3 to 144 months after initial relief (median, 48 months). Fifty-three
patients (10.5%) developed new or increased subjective facial sensory symptoms and one
developed deafferentation pain; in
17 this resolved. Patients who developed
sensory loss had better long-term pain control (78% at five years).
The main limitation of this study is
its retrospective nature and lack of a specific control group. We are continuing to collect outcomes data on all subjects.
Gamma knife radiosurgery was an effective minimal-access approach for medically
refractory trigeminal neuralgia. Some degree of facial sensory loss may improve
long term pain relief and usually is not bothersome. Pain recurrence can be managed with repeat
radiosurgery or a different procedure.
This study establishes clinical
outcomes for trigeminal neuralgia radiosurgery so that patients and doctors can
compare radiosurgery to other medical or surgical treatments. Because the dataset is large, this data will
be of value for the design of randomized trials. Data Share 1: Patient Characteristics
|# of patients (Count)||Trigeminal Neuralgia-age (Avg)||Trigeminal Neuralgia-years with TGN (Avg)||Trigeminal Neuralgia-Number of prior surgeries (Count)||Trigeminal Neuralgia-typical (TN I) (Count)||Trigeminal Neuralgia-atypical (TN II) (Count)||nerve division-V1 (Percentage)||nerve division-V1-2-3 (Percentage)||nerve division-V2 (Percentage)||nerve division-V2-3 (Percentage)||nerve division-V3 (Percentage)|
Medical therapy is the mainstay of trigeminal neuralgia (TN) management but patients frequently require surgical intervention due to persistent pain or treatment-related side effects. Available surgeries include microvascular
decompression via craniotomy or percutaneous rhizotomies such as radiofrequency
thermooagulation, balloon microcompression or glycerol rhizotomy.17
These procedures have
variable but definite rates of risk and pain recurrence and clinicians often choose between them based on these outcomes.
Gamma Knife radiosurgery (GKSR) is a minimally
invasive surgical approach to create a lesional effect with tumors, blood
vessels, or nerve fibers (axons). It can be used to manage trigeminal neuralgia
via precise targeting of the trigeminal nerve anterior to the brainstem. Lars Leksell first performed radiosurgery using
a prototype guiding device linked to an x-ray tube.13,14
Since then, modern radiosurgery devices have
been used for this indication. It is important to understand the value of radiosurgery for this pain disorder.3,5,7,9,10,15,16,19-23,25
Our hypothesis was that through
retrospective evaluation of a large patient series who had this procedure, we
could determine not only how well it worked but determine an accurate morbidity profile.
Thus, we evaluated the effectiveness of GKSR over
time, how quickly relief was achieved, whether relief was durable, and
determined factors associated with success or complications to help clinicians
and patients choose amongst various options.
Prior reports found that radiosurgery
was well tolerated and could be performed on an outpatient basis, that
approximately 80% of patients had some form of pain relief and that side
effects were related to dose and treatment technique. 3,5,7,10,15,16,19-23,25
The main limitation of our study method
was that data was evaluated retrospectively (although collected prospectively).
This study was approved by the University of
Pittsburgh Institutional Review Board.
The work described in this report was funded by a grant to
Dr. Kano from the Osaka Medical
Research Foundation for Incurable Diseases.
Between 1992 and 2011, 1,000 GKSR procedures were performed for trigeminal neuralgia
patients including 156 repeat GKSR
procedures. The median age was 70 years (range 16–99 years).
In this complete series, there were 396 men and 604 women.
All patients had longstanding pain refractory to medical management
using agents such as carbamazepine, phenytoin, baclofen, or gabapentin. Within the cohort of 503 patients with idiopathic TGN suitable for evaluation, the median symptom duration was 84 months (range
3–444 months). Pain was distributed in the V2 and V3
distributions of the trigeminal nerve (56%), followed by V3 (15%), V2 (12%), V1 and V2 (12%), all trigeminal distributions (2.0%) and only V1 plus V3 (1%). Surgery had been performed previously in 215 (42%) patients
and multiple surgeries had been performed in 57%. GKSR
was the first surgery in 288 (58%) of patients. The subset of 503 patients suitable for outcomes analysis were part of a cohort evaluated up to 200912
. Those managed after 2009 were censored from the outcomes analysis but were included in our study of the technique. The characteristics of these patients were similar to the entire clinical experience.
All patients reported the typical features of
trigeminal neuralgia as a sharp, lancinating or shooting electric-shock type of
pain often triggered by facial activity or stimulation. Twenty-six (6%) noted additional features such as a more constant dull, aching, or burning
pain. In addition, 103 (20.4%) had some sensory disturbance (usually
paresthesias) preoperatively, and three patients (0.5%) had partial deafferentation pain caused by prior ablative surery.
Different models of the Gamma Knife (Elekta,
Stockholm Sweden)(models U, A ,
B, C, 4C, and Perfexion) were used during this study. A single 4-mm isocenter
was used in 953 patients (95%) and two 4-mm
isocenters were used in the rest. With a single isocenter, the target
was 3 to 8 mm anterior from the junction of the trigeminal nerve and pons. We administered maximum doses
of 60 (2%), 70 (4%), 75 (3%), 80
(88%), 85 (2%), and 90 Gy (2%). The radiosurgical target initially was closer to the pons and over time moved 1-2 mm anterior but remained a posterior nerve target in the majority of patients. Because some patients had a short nerve segment or because of prior surgery had a nerve that was difficult to identify along the entire course, a mid-nerve target or an anterior target was chosen in individual patients.
We evaluated the degree of pain relief, the latency interval
until pain relief, the need for further surgical procedures, the use of
medications, and the development of new symptoms or signs. To evaluate the
effectiveness of GKSR we calculated the time to initial response and the
duration of pain relief using the Kaplan–Meier product -limit method. Pain outcome
was scored using the Barrow Neurological Institute (BNI) scale, as shown in
Data Share 2. We defined BNI scores I to IIIb as representing favorable outcomes, whereas BNI
scores of IV and V were defined as treatment failures. For patients who described facial sensory
dysfunction, we also inquired about their quality of life related to trigeminal
neuralgia and whether sensory symptoms bothered them. BNI scores were as follows: I (no pain and taking no medication); II (occasional pain but taking no medication); IIIa (no pain but taking medication); IIIb (pain improved but not adequately controlled with medication); IV (some pain, not adequately controlled with medication); V (no relief). The first follow-up was at 3 months or earlier if the patient requested an evaluation due to poor pain control, and then requested yearly. Patients who became pain free were later contacted in 2009 for a late evaluation.
Within the evaluation cohort of 503 patients, 83% completed follow-up. Forty-two patients did not have follow-up data and
were excluded from the analysis.
All serial follow-up information was obtained via direct
contact with the patient or their referring physicians. This data was collected
by neurosurgeons who had not participated in patient care using telephone
The tests and scoring methods were
outcomes with various clinical parameters (including sex, age, duration of
symptoms, presence or absence of preoperative sensory dysfunction, presence of
atypical pain features, number of previous failed surgical procedures, and
maximum dose), using a log rank test with p<.05 set as significant,
a stepwise (forward conditional)
multivariate analyses and the Cox proportional hazards model with p<.10 set as signficant. Outcomes
were calculated using actuarial statistics over a 16 year period. The median
follow-up duration was 2 years (median 24, range 3–156 months).
We did not use a power calculation as
no control group was studied.
Data Share 2: Pain Relief OutcomesBNI Grade, Relief at Last Follow-up
was chosen as the level of statistical significance for the log-rank test.
|# of patients (Count)||BNI grade-I (Count)||BNI grade-II (Count)||BNI grade-IIIa (Count)||BNI grade-IIIb (Count)||BNI grade-IV (Count)||BNI grade-V (Count)||Trigeminal Neuralgia-sensory dysfunction (Count)||Trigeminal Neuralgia-sensory dysfunction (Percentage)||Trigeminal Neuralgia-anesthesia dolorosa (Count)|
From the cohort analyis of 503 patients, 449 (89%) responded to GKSR after the procedure at a median latency of one
month. The median interval until pain relief (grade I to IIIb) was
one month. The duration of pain relief after the initial response was evaluated
using the product limit method of Kaplan and Meier. Pain relief (grade I, II, IIIa or IIIb) was achieved and maintained in 375 patients (75%) at 1
year, 297 patients (59%) at 2 year, 217 patients (43%) at 5 years and 143
patients (29%) at 10 years. At the final
evaluation, 330 (66%) patients continued to have pain control (BNI grade
I-IIIb). One hundred and forty-four patients (29%) achieved group I, 11 patients (2%) were group II, 120 patients (24%)
were group IIIa, 55 patients (11%) were group IIIb, 126 patients (25%) were group
IV, and 47 patients were group V pain status (9%). Pain eventually recurred in
240 patients at a median of 48 months (range, 3-144 months). Additional surgery was performed in 144
All procedures were successfully concluded without
incident. Fifty-three patients (10.5%) later developed increased facial sensory dysfunction such as paresthesias
or objective facial sensory loss, all within the first two years. In ten of these (19%) a later recurrence of pain was also found. The 1-, 3-, and 5-year rates for maintenance of pain relief in patients who noted
sensory dysfunction were 91%, 82.0%, and 78%, respectively.
these 53 patients further to understand the effect of sensory dysfunction on
their quality of life. Thirteen could not be contacted and five of these had
died. In seventeen, the symptoms had
resolved (16 described their quality of life to be improved after radiosurgery). Of 23 with persistent dysfunction, seven
described it as “not bothersome”, ten as “mildly bothersome”, six as “severely
bothersome”, and zero as “intolerable”. Nineteen of these said their quality of
life was improved after GKSR and that sensory dysfunction was a good
“trade-off” for pain relief. Four said
their quality of life was worse. One patient (0.2%) who already had
decreased facial sensation after a prior microvascular decompression developed deafferentation pain after 75 Gy GKSR
with two isocenters. No other trigeminal deficit (such as motor function or chewing) or other
cranial neuropathy was found.
Management of Recurrent Pain
Because of recurrent pain, 87 patients underwent a second radiosurgery
and 72 were suitable for this analysis. Although the techniques varies amongst
centers, we targeted the nerve a few mm anterior to the first target to allow
some overlap. This becomes simpler with
a longer nerve length. The median interval between procedures was 30 months, and subsequent follow-up averaged two years. The average
age was 78. The maximum dose at the
second radiosurgery varied between 60 and 70 Gy. After the second GKSR, 68 patients (94%) had
pain relief at some time. The actuarial rate for pain control was 90%, 73%,
63%, 56% at 1-, 3-, 5-, 10-years respectively. Eight patients (11%) developed
new sensory dysfunction after the second radiosurgery which was permanent in six.
with earlier initial pain relief (grade I to IIIB) were absence
of atypical trigeminal neuralgia features (p=0.014), no prior surgery
(p=0.014), and pain for < 3 years before GKSR (p=0.01). A shorter pain duration before GKSR was not correlated with a grade I
Factors associated with earlier pain
recurrence were age < 65 years (univariate:p=0.012, multivariate: p=.06),
patients with atypical pain features (univariate,p=0.02, multivariate, p=.04),
> 3 surgeries univariate:p=0.03, multivariate:p=.095), and patients without any new facial sensory symptoms (multivariate: p<.0001).
The goal of trigeminal neuralgia surgery is complete
elimination of pain and need for medication. To achieve this, there is a balance between surgical risk, maintenance
of normal nerve function, and the known rates for pain relief. Not all procedures relieve pain and not all
patients choose to stop medication, particularly if they have been taking it for years. For patients who have failed one or
more prior surgeries, the expectations for complete relief are reduced.
Unfortunately, since pain can come and go, a patient may report that they have
no pain at one assessment (grade I), only to have it recur soon afterwards
(grade II or worse) but not report it.
The role of radiosurgery in the management of
medically refractory trigeminal neuralgia has evolved. Questions regarding
treatment durability, long-term complications, and appropriate patient
selection mandate that analyses of radiosurgical outcomes be available to
compare with reports on other options.26
Other centers have found a latency interval to pain
relief after radiosurgery of four to eight weeks.10,12,18,28 We found that 89% of patients noted significant
improvement at an average of one month. We found that patients with typical trigeminal
neuralgia, patients who underwent GKSR as their initial surgical procedure, and
patients who underwent earlier GKSR (< 3 years) after pain onset had faster
pain relief (grade I to IIIb). By 12 months after GKSR, 11% of patients still
had pain. We advocate repeat GKSR only if complete pain relief had been
achieved initially, with subsequent recurrence.18
The majority of patients experience lasting and meaningful pain reduction with few complications after GKSR. In this series,
75% of patients achieved or maintained pain control (BNI grade I-IIIb), 59% had
pain relief at 3 years, 43% maintained relief at 5 years, and 29% were still
controlled with or without medications at 10 years. The best result, BNI grade I (pain free-off medication), was achieved in 28% of patients. Of those with a
significant pain recurrence, 60% underwent further surgery and 40% were
maintained on medication alone. Clearly, pain control can lessen over time necessitating further medical or surgical management. In a prior analysis we did not find that the radiosurgical dose rate correlated with outcome.1
Post-rhizotomy paresthesias or numbness of varying
degrees is observed in 6 to 70% of patients after thermal rhizotomy, glycerol
rhizotomy, or balloon microcompression, depending on the technique and the goal
of the surgeon. 3,4,6,7,10,18,24,27 In our study, sensory dysfunction was found
in 11%. Only one patient (0.19%) developed
deafferentation pain. This patient had undergone a prior microvascular decompression. Only ten of 53 patients who later developed
facial sensory dysfunction had pain recurrence after GKSR. The 1-, 3-, and
5-year rates for maintenance of pain relief in patients who later developed
facial sensory symptoms were 91%, 82%, and 78%, respectively. These data suggest
that patients who developed facial sensory symptoms had a reduced rate of recurrent
Gamma knife radiosurgery is effective for trigeminal neuralgia and associated with low risk. This procedure
maintains facial sensation in most patients, and can be performed regardless of age
or medical condition. The use of a
higher dose may provide better and longer-lasting outcomes although this remains to be seen. In patients with recurrent pain, a repeat
GKSR procedure may reestablish pain control. However, these outcomes are not as good as those after a
first microvascular decompression, 2 and thus we
continue to recommend consideration of that approach for younger patients suitable for invasive
Future work should consider randomized trials between
radiosurgery and medical therapy for patients who have failed medication at
least once. The Author(s) wish to thank:Project Roles:
D. Kondziolka (Performed Research), H. Kano (Performed Research), A. Niranjan (Performed Research), L. Lunsford (Performed Research), J. Flickinger (Performed Research)
D. Kondziolka (Consultant, Elekta); (Officer, SciencEngines), L. Lunsford (Shareholder, Elekta)1. Arai, Y.,Lunsford, LD.,Kano, H.,Niranjan, A.,Flickinger , JC.,Kondziolka, D., Does the gamma knife dose rate affect outcomes in trigeminal neuralgia radiosurgery?. J Neurosurg 113: 168 - 171, 20102. Barker, FG.,Jannetta, PJ.,Bissonette, D.,Larkins, M.,Jho, HD., The long-term outcome of microvascular decompression for trigeminal neuralgia. NEJM 334: 1077 - 1083, 19963. Brisman , R., Gamma knife radiosurgery for primary management for trigeminal neuralgia. J Neurosurg (Suppl) 93: 159 - 161, 20004. Brisman, R.,Mooij, R., Gamma knife radiosurgery for trigeminal neuralgia: dose-volume histograms of the brainstem and trigeminal nerve. J Neurosurg (Suppl) 93: 155 - 158, 20005. Chen, JC.,Greathouse, HE.,Girvigian, M.,Miller, MJ.,Liu , A.,Rahimian, J., Prognostic factors for radiosurgery treatment of trigeminal neuralgia. Neurosurgery 62: 53 - 60, 20086. Flickinger, JC.,Pollock, B.,Kondziolka, D.,Phuong, L.,Foote, K.,Stafford, S., Does increased nerve length within the treatment volume improve trigeminal neuralgia radiosurgery?. Int J Radiat Oncol Biol Phys 51: 449 - 454, 20017. Kano, H.,Kondziolka, D.,Yang, HC.,Zorro, O.,Lobato-Polo, J.,Flannery , T., et al: Outcome predictors after gamma knife radiosurgery for recurrent trigeminal neuralgia. Neurosurgery 67: 1637 - 1645, 20108. Kanpolat, Y.,Savas, A.,Bekar, A.,Berk, C., Percutaneous controlled radiofrequency trigeminal rhizotomy for the treatment of idiopathic trigeminal neuralgia: 25-year experience with 1,600 patients. Neurosurgery 48: 524 - 532, 20019. Kondziolka, D.,Lunsford, LD.,Flickinger, JC., Stereotactic radiosurgery for the treatment of trigeminal neuralgia. Clin J Pain 18: 42 - 47, 200210. Kondziolka, D.,Lunsford, LD.,Flickinger , JC.,Young, RF.,Vermeulen, S.,Duma, C., et al: Stereotactic radiosurgery for trigeminal neuralgia: a multiinstitutional study using the gamma unit. J Neurosurg 84: 940 - 945, 199611. Kondziolka, D.,Perez, B.,Flickinger, JC.,Habeck, M.,Lunsford, LD., Gamma knife radiosurgery for trigeminal neuralgia: results and expectations. Arch Neurol 55: 1524 - 1529, 199812. Kondziolka, D.,Zorro, O.,Lobato-Polo, J.,Kano, H.,Flickinger , JC.,Lunsford, LD., Gamma knife stereotactic radiosurgery for idiopathic trigeminal neuralgia. J Neurosurg 112: 758 - 765, 201013. Leksell, L., Sterotaxic radiosurgery in trigeminal neuralgia. Acta Chir Scand 137: 311 - 314, 197114. Lindquist, C.,Kihlstrom, L.,Hellstrand, E., Functional neurosurgery--a future for the gamma knife?. Stereotact Funct Neurosurg 57: 72 - 81, 199115. Little, A.,Shetter, AG.,Shetter, M.,Bay, C.,Rogers, C., Long-term pain response and quality of life in patients with typical trigeminal neuralgia treated with gamma knife stereotactic radiosurgery. Neurosurgery 63: 915 - 923, 200816. Little, AS.,Shetter, AG.,Shetter, ME.,Kakarla, UK.,Rogers, CL., Salvage gamma knife stereotactic radiosurgery for surgically refractory trigeminal neuralgia. Int J Radiat Oncol Biol Phys 74: 522 - 527, 200917. Lunsford, LD.,Apfelbaum, R., Choice of surgical therapeutic modalities for treatment of trigeminal neuralgia: microvascular decompression, percutaneous retrogasserian thermal, or glycerol rhizotomy. Clin Neurosurg 32: 319 - 333, 198518. Maesawa, S.,Salame, C.,Flickinger, JC.,Pirris, S.,Kondziolka, D.,Lunsford, LD., Clinical outcomes after stereotactic radiosurgery for idiopathic trigeminal neuralgia. J Neurosurg 94: 14 - 20, 200119. McNatt, SA.,Yu, C.,Giannotta, S.,Zee, C.,Apuzzo, MLJ.,Petrovich, Z., Gamma knife radiosurgery for trigeminal neuralgia. Neurosurgery 56: 1295 - 1301, 200520. Pollock, BE., Comparison of posterior fossa exploration and stereotactic radiosurgery in patients with previously nonsurgically treated idiopathic trigeminal neuralgia. Neurosurg Focus 18: 1 - 6, 200521. Pollock , BE.,Foote, R.,Link, M.,Stafford, S.,Brown, PD.,Schomberg, PJ., Repeat radiosurgery for idiopathic trigeminal neuralgia. Int J Radiat Oncol Biol Phys 61: 192 - 195, 200522. Pollock, BE.,Phuong , LK.,Foote, R.,Stafford , S.,Gorman, DA., High-dose trigeminal neuralgia radiosurgery associated with increased risk of trigeminal nerve dysfunction. Neurosurgery 49: 58 - 62, 200123. Pollock, BE.,Phuong , LK.,Gorman, D.,Foote, R.,Stafford SL, ., Stereotactic radiosurgery for idiopathic trigeminal neuralgia. J Neurosurg 97: 347 - 353, 200224. Regis , J.,Metellus, P.,Dufour, H.,Roche, PH.,Muracciole, X.,Pellet, W., et al: Long-term outcome after gamma knife surgery for secondary trigeminal neuralgia. J Neurosurg 95: 199 - 205, 200125. Regis , JM.,Metellus, P.,Hayashi, M.,Roussel, P.,Donnet, A.,Bille-Turc, F., Prospective controlled trial of gamma knife surgery for essential trigeminal neuralgia. J Neurosurg 104: 913 - 924, 200626. Sheehan, J.,Pan, HC.,Stroila, M.,Steiner, L., Gamma knife surgery for trigeminal neuralgia: outcomes and prognostic factors. J Neurosurg 102: 434 - 441, 200527. Shetter, AG.,Rogers, C.,Ponce, F.,Fieldler, JA.,Smith, K.,Speiser, BL., Gamma knife radiosurgery for recurrent trigeminal neuralgia. J Neurosurg 97: 536 - 538, 200228. Young, RF.,Vermeulen, SS.,Grimm, P.,Blasko, J.,Posewitz, A., Gamma Knife radiosurgery for treatment of trigeminal neuralgia: idiopathic and tumor related. Neurology 48: 608 - 614, 199729. Zorro, O.,Lobato-Polo, J.,Kano, H.,Flickinger, JC.,Lunsford, LD.,Kondziolka, D., Gamma knife radiosurgery for multiple sclerosis-related trigeminal neuralgia. Neurology 73: 1149 - 1154, 2009